Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Rejection Of Narrowed Indication For Daxas Led To Negative Panel Vote

Executive Summary

If FDA had accepted Forest's proposed revised indication for Daxas (roflumilast), the chronic obstructive pulmonary disease drug could have yielded a different outcome from the Pulmonary-Allergy Drugs Advisory Committee
Advertisement

Related Content

FDA Questions CV Events, Small Database Heading Into Aclidinium Bromide Advisory Committee
Positive COPD Data Allows Forest To File For Approval of Eklira in 2011
Positive COPD Data Allows Forest To File For Approval of Eklira in 2011
Forest Ends Phenomix Partnership, But Says Its Many Deals Are Bearing Fruit
Forest Ends Phenomix Partnership, But Says Its Many Deals Are Bearing Fruit
Forest Acquires U.S. Rights To Nycomed's Oral COPD Drug Daxas
Forest Acquires U.S. Rights To Nycomed's Oral COPD Drug Daxas
Nycomed Says Phase III Daxas COPD Data Show Drug Is Ready For A Second Shot

Topics

Advertisement
UsernamePublicRestriction

Register

PS052112

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel